Cargando…
Riociguat: Something new in pulmonary hypertension therapeutics?
Pulmonary hypertension (PH) continues to be a disease that is associated with woeful outcomes. The search for an ideal drug molecule for PH led to the discovery of riociguat, which is a first-in-class drug molecule that activates soluble guanylate cyclase. We conducted a systematic literature search...
Autores principales: | Shanmugam, Elangovan, Jena, Amrita, George, Melvin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319244/ https://www.ncbi.nlm.nih.gov/pubmed/25709345 http://dx.doi.org/10.4103/0976-500X.149132 |
Ejemplares similares
-
Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019) -
Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020) -
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022) -
Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011) -
Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat
por: Smith, Zachary R, et al.
Publicado: (2016)